BML-210
Based on 2 publication(s) in Google Scholar
BML-210 is a potent HDAC inhibitor. BML-210 can inhibit the HDAC4-VP16-driven reporter signal with an apparent IC50 of ∼5 µM. BML-210 has a specific disruptive effect on the HDAC4:MEF2 interaction. BML-210 causes an increase in the G0/G1 phase. BML-210 induces apoptosis and displays antitumour activities in orthotopic mammary tumours in mice.
商品は「研究用試薬」です。人や動物の医療用・臨床診断用・食品用の製品ではありません。
研究用途以外に使用した場合、当社は一切の責任を負いかねます。
- 純度: 98.04%
- CAS 番号: 537034-17-6
- 分子式: C20H25N3O2
- 分子量:339.43
-
保管条件:Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 2 years , -20°C, 1 year
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
生物活性
-
化学情報
-
溶剤 & 溶解度
- 純度とドキュメンテーション
- 参考文献
-
Help & FAQs
-
Reprogramming Compound Library
HY-L039
-
Oxygen Sensing Compound Library
HY-L045
-
Anti-Breast Cancer Compound Library
HY-L074
-
Anti-Pancreatic Cancer Compound Library
HY-L077
-
Anti-Blood Cancer Compound Library
HY-L079
-
Anti-Liver Cancer Compound Library
HY-L101
-
Osteogenesis Compound Library
HY-L131
-
Highly Selective Inhibitors Library
HY-L158
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Anti-Hematopathy Compound Library
HY-L171
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Anti-Brain Cancer Compound Library
HY-L188
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
High-Efficiency Gene Editing Compound Library
HY-L244
-
Lactylation Compound Library
HY-L249
-
Apoptosis Compound Library
HY-L003
-
Cell Cycle/DNA Damage Compound Library
HY-L004
-
Epigenetics Compound Library
HY-L005
-
Histone Modification Research Compound Library
HY-L024
-
Anti-Cancer Compound Library
HY-L025
-
Anti-Aging Compound Library
HY-L034
MedChemExpress（MCE）の使用を引用している文献 BML-210
More
生物活性
|
HDAC4:MEF2 |
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HeLa | IC50 |
87 μM
Compound: 4c, BML-210
|
Inhibition of HDAC in human HeLa cell extract by fluorescence plate reader assay
Inhibition of HDAC in human HeLa cell extract by fluorescence plate reader assay
|
[PMID: 16921367] |
| MV4-11 | IC50 |
7244 nM
Compound: 4
|
Antiproliferative activity against human MV4-11 cells
Antiproliferative activity against human MV4-11 cells
|
[PMID: 35580726] |
BML-210 (10, 20 μM; 24, 48 hours) inhibits cell proliferation and growth inhibition of NB4 cells[2].
BML-210 (10, 20 μM; 24, 48 hours) causes a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase[2].
BML-210 (10, 20 μM; 24, 48 hours) causes cytotoxic effects on NB4 cells at 20 μM. BML-210 at a dose of 10 μM induces apoptotic cell death[2].
BML-210 (10, 20 μM; 24, 48 hours) inhibits HDAC Expression and Activity in NB4 Cells[2].
BML-210 (1.0 μM; for 48 h) causes higher expression levels differential expressed genes (DEGs) in mouse EO771 cells[3].
BML-210 does not reduce the expression of HDAC4-VP16[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:NB4 cells
-
Concentration:10, 20 μM
-
Incubation Time:24, 48 hours
-
Result:Inhibited cell proliferation and growth inhibition of NB4 cells in a dose- and time-dependent manner.
-
Cell Line:NB4 cells
-
Concentration:10, 20 μM
-
Incubation Time:24, 48 hours
-
Result:Caused a decrease in the proportion of NB4 cells in the S phase and an increase in the G0/G1 phase.
Caused an increase in the G0/G1 phase up to 70% at 24 and 48 h with 10 μM.
-
Cell Line:NB4 cells
-
Concentration:10, 20 μM
-
Incubation Time:24, 48 hours
-
Result:Caused cytotoxic effects on NB4 cells in a dose- and time-dependent manner.
-
Cell Line:NB4 cells
-
Concentration:10, 20 μM
-
Incubation Time:24, 48 hours
-
Result:At a dose of 10 μM induced apoptotic cell death.
-
Cell Line:NB4 cells
-
Concentration:10, 20 μM
-
Incubation Time:24, 48 hours
-
Result:At 10 μM dose inhibited HDAC1 gene expression up to 36% after 48 h of treatment Inhibited HDAC expression up to 74% at 8 h point at 20 μM.
Had very low effect on HDAC 2 and HDAC 3 expression.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female C57BL/6 mice with mouse breast cancer EO771 cells[3]
-
Dosage:20 mg/kg
-
Administration:IP; three times per week for two weeks
-
Result:Notably suppressed the tumour growth and weight.
化学情報
-
CAS 番号 537034-17-6
-
性状 Solid
-
分子量 339.43
-
分子式 C20H25N3O2
-
Color White to off-white
-
SMILES
O=C(NC1=CC=CC=C1N)CCCCCCC(NC2=CC=CC=C2)=O
-
輸送条件
Room temperature in continental US; may vary elsewhere.
-
保管条件
Powder -20°C 3 years 4°C 2 years In solvent -80°C 2 years -20°C 1 year
Publications (2)
-
Journal Impact Factor
-
Most Recent
-
J Mol Med (Berl)
2019 Aug;97(8):1183-1193. PMID: 31201471 -
Transl Stroke Res
HDAC9 Deficiency Upregulates cGMP-dependent Kinase II to Mitigate Neuronal Apoptosis in Ischemic Stroke. [Abstract]2025 Jun;16(3):868-881. PMID: 38940872
溶剤 & 溶解度
DMSO : ≥ 30 mg/mL (88.38 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
濃度 (開始) × 体積 (開始) = 濃度 (終了) × 体積 (終了)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL.
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
純度とドキュメンテーション
-
データシート (276 KB)
-
SDS (760 KB)
- English - EN (760 KB)
- Français - FR (760 KB)
- Deutsch - DE (760 KB)
- Norwegian - NO (760 KB)
- Español - ES (760 KB)
- Swedish - SV (760 KB)
- Italian - IT (760 KB)
- Korean - KR (760 KB)
- Portuguese - PT (760 KB)
-
取扱説明書 (2659 KB)
参考文献
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 2.9461 mL | 14.7306 mL | 29.4612 mL | 73.6529 mL |
| 5 mM | 0.5892 mL | 2.9461 mL | 5.8922 mL | 14.7306 mL | |
| 10 mM | 0.2946 mL | 1.4731 mL | 2.9461 mL | 7.3653 mL | |
| 15 mM | 0.1964 mL | 0.9820 mL | 1.9641 mL | 4.9102 mL | |
| 20 mM | 0.1473 mL | 0.7365 mL | 1.4731 mL | 3.6826 mL | |
| 25 mM | 0.1178 mL | 0.5892 mL | 1.1784 mL | 2.9461 mL | |
| 30 mM | 0.0982 mL | 0.4910 mL | 0.9820 mL | 2.4551 mL | |
| 40 mM | 0.0737 mL | 0.3683 mL | 0.7365 mL | 1.8413 mL | |
| 50 mM | 0.0589 mL | 0.2946 mL | 0.5892 mL | 1.4731 mL | |
| 60 mM | 0.0491 mL | 0.2455 mL | 0.4910 mL | 1.2275 mL | |
| 80 mM | 0.0368 mL | 0.1841 mL | 0.3683 mL | 0.9207 mL |
BML-210 関連分類
HY-19350 関連分類
Powered by Bioz